Additionally, Ouchi et al. identified FN1 as a fusion partner of ALK by 5′RACE, FN1-ALK, resulted in ALK overexpression in the inflammatory myofibroblastic tumors, and this finding should facilitate development of novel therapeutics (Ouchi et al., 2015). This evidence concerns the gene FN1 and inflammatory myofibroblastic tumor.